Nervgen Pharma (NGEN) Non-Current Assets (2024 - 2026)

Nervgen Pharma (NGEN) has reported Non-Current Assets for 3 consecutive years, with $275626.1 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Assets changed N/A year-over-year to $275626.1 in Q2 2026; TTM through Jun 2026 was $1.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $293405.2, down 15.13% from the prior year.
• Non-Current Assets was $275626.1 for Q2 2026 at Nervgen Pharma, down from $288192.3 in the prior quarter.
• Over five years, Non-Current Assets peaked at $338830.7 in Q4 2024 and troughed at $275626.1 in Q2 2026.
• A 3-year average of $299013.6 and a median of $290798.7 in 2025 frame the typical range for Non-Current Assets.
• The widest YoY moves for Non-Current Assets: up 13.41% in 2025, down 13.41% in 2025.
• Over 3 years, Non-Current Assets stood at $338830.7 in 2024, then fell by 13.41% to $293405.2 in 2025, then declined by 6.06% to $275626.1 in 2026.
• The last three Non-Current Assets figures came in at $275626.1 (Q2 2026), $288192.3 (Q1 2026), and $293405.2 (Q4 2025), per Business Quant data.